InvestorBrandNetwork (IBN) logo

InvestorBrandNetwork (IBN)

The latest articles, editorials and news releases from InvestorBrandNetwork (IBN), a growing Investor Brand Platform.

RSS Feed for InvestorBrandNetwork (IBN)

Fund Manager Forecasts Gold’s Return to $5,000 Price Level

August 14, 2026Gold could eventually climb back to $5,000 an ounce, although investors may have to wait several years for the metal to reach that level. This is according to David Miller, CIO and co-founder of Catalyst Funds and portfolio manager of the Strategy Shares Gold Enhanced Yield ETF.


Regentis Biomaterials Ltd. (NYSE American: RGNT) Moves GelrinC Along Parallel US Clinical and European Commercial Tracks

August 14, 2026 Regentis has passed 50% enrollment in the pivotal Phase III SAGE study of GelrinC, with recruitment completion targeted for the third quarter of 2026 and a PMA process expected to begin by the end of 2027. FDA approved a single-arm protocol using a historical microfracture control data package the company owns, and Regentis reports that the first 40 patients closely match that control group.


InvestorNewsBreaks – American Fusion Inc. (OTC: AMFN) Highlights Growing Power Demand, Advances Texatron(TM) Commercialization Strategy

August 14, 2026American Fusion (OTC: AMFN) provided an industry and market update highlighting accelerating fusion investment and growing electricity demand from artificial intelligence data centers, hospitals and other mission-critical infrastructure. The company is developing its Texatron(TM) Fusion Engine(TM) as a potential scalable source of distributed electricity, with a long-term Power-as-a-Service model under which American Fusion would own, operate and maintain generating assets and sell electricity directly to customers behind the meter.


MissionIRNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Advances Heart Attack Detection Program, Extends Cash Runway Into 2027

August 14, 2026HeartBeam (NASDAQ: BEAT) reported second-quarter 2026 financial and operational results, highlighting progress across its heart attack detection program, 12-lead ECG extended wear patch and initial commercial launch. The company completed enrollment of 134 patients in its ALIGN-ACS pilot study ahead of schedule, with full results expected to be presented at TCT 2026, and surpassed 50% enrollment in its 500-patient HEADSTART-ACS pilot study.


MissionIRNewsBreaks – AZIO AI Holdings, Inc. (NASDAQ: AZIO) Featured in NetworkNewsAudio on AI Power and Infrastructure Constraints

August 14, 2026AZIO AI Holdings (NASDAQ: AZIO) is featured in a NetworkNewsAudio Audio Press Release examining how power availability, specialized data-center capacity and high-speed connectivity are emerging as critical constraints on AI expansion. The editorial highlights AZIO AI’s planned 500-megawatt AI data-center campus in Texas, which is designed to address these infrastructure challenges by securing power and connectivity in parallel.


InvestorNewsBreaks – Datavault AI Inc. (NASDAQ: DVLT) Appoints Intellectual Property Veteran Dean Becker as Chief Licensing Officer

August 14, 2026Datavault AI (NASDAQ: DVLT) has appointed Dean Becker as chief licensing officer, giving him executive responsibility for the licensing, valuation and monetization of the company’s global intellectual property portfolio. Becker brings more than 30 years of experience and has completed billions of dollars in intellectual property-based transactions, including creating the Ocean Tomo patent auction business and later serving for a decade as CEO of multiple ICAP intellectual property businesses.


NetworkNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Advances AI-Driven Oncology Pipeline, Establishes Open Medicine AI

August 14, 2026Lantern Pharma (NASDAQ: LTRN), reported second-quarter 2026 operational and financial results, highlighting progress across its AI-driven oncology pipeline and the establishment of Open Medicine AI (“OMAI”) as a separate company. Emerging data from the Phase 2 HARMONIC(TM) trial showed LP-300’s progression-free survival benefit deepening with treatment duration in patients with EGFR exon 21 L858R mutations, while the FDA reviewed key protocol amendments without objection.


InvestorNewsBreaks – Moody Capital Solutions Appoints Steve Kann as Managing Director

August 13, 2026Moody Capital announced that Steve Kann has joined the investment bank as managing director, focusing on capital raising and advisory engagements for growth companies. Kann brings more than 30 years of experience in corporate finance, equity research and strategic advisory and has participated as a founder, advisor, agent, banker and investor across dozens of companies.